权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

MURINE ANTI-ID ANTIBODIES FOR IMMUNOTHERAPY OF MELANOMA

用于黑色素瘤免疫治疗的鼠抗 ID 抗体

基本信息

批准号：
3493064
负责人：
CARL Venton HAMBY
金额：
$ 5万
依托单位：
VIRO DYNAMICS CORPORATION
依托单位国家：
美国
项目类别：
财政年份：
1992
资助国家：
美国
起止时间：
1992-09-30 至 1993-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/3493064
关键词：
active immunization antiidiotype antibody antitumor antibody human subject humoral immunity immunoconjugates immunoregulation melanoma monoclonal antibody neoplasm /cancer immunotherapy neoplastic cell serology /serodiagnosis technology /technique development tumor antigens

项目摘要

The long range goal of this program is to develop and market mouse antiidiotypic (anti-id) monoclonal antibodies (MoAb) which bear the internal image of human high molecular weight-melanoma associated antigen (HMW-MAA) for active specific immunotherapy in patients with melanoma. This proposal stems from investigations in BALB/c mice which have shown that conjugation to KLH and administration with an adjuvant markedly enhances the ability of the mouse anti-id MoAb MK2-23 to induce humoral and cellular immunity towards the HMW-MAA. The specific goal of this proposal is to determine the effect of conjugation with KLH and/or administration with BCG of mouse anti-id MoAb MK2-23 (which bears the internal image of HMW-MAA) on the induction of humoral anti HMW-MAA immunity in patients with melanoma and to correlate the development of anti HMW-MAA immunity with the clinical course of the disease. The data obtained to date in mouse studies and limited clinical trials indicate that immunization of individuals with anti-id MoAb bearing the internal image of HMW-MAA can induce specific immune responses to this antigen. Moreover, the clinical trials have demonstrated an association between anti HMW-MAA immunity and prolonged patient survival. These investigations are designed to optimize the immunization protocols with anti-id MoAb and provide further evidence for the feasibility of this approach in the active specific immunotherapy of patients with melanoma.

该计划的长期目标是开发和销售鼠标抗独特型(抗id)单抗(MOAB) 人高分子黑色素瘤相关抗原的内成像 (HMW-MAA)用于黑色素瘤患者的主动特异性免疫治疗。这一建议源于对BALB/c小鼠的研究，该研究表明与KLH的结合和辅助剂的给药明显增强小鼠抗id抗体MK2-23诱导体液免疫的能力以及对HMW-MAA的细胞免疫。这一行动的具体目标是建议确定与KLH和/或结合的效果卡介苗给药小鼠抗id单抗MK2-23 HMW-MAA在体液抗HMW-MAA诱导中的内成像黑色素瘤患者的免疫功能及其与肿瘤发生的相关性抗HMW-MAA免疫与疾病的临床病程有关。数据迄今为止在小鼠研究和有限的临床试验中获得的数据表明对体内携带抗id摩押的人进行免疫 HMW-MAA的图像可以诱导对该抗原的特异性免疫反应。此外，临床试验表明，抗HMW-MAA免疫和延长患者生存期。这些调查旨在通过以下方式优化免疫方案反id摩押，并为其可行性提供进一步的证据黑色素瘤患者主动特异性免疫治疗的探讨